eptifibatide

Known as: eptifibatide [Chemical/Ingredient], L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-prolyl-, cyclic(1-6)-disulfide, epifibatide 
A cyclical heptapeptide with anticoagulant activity. Eptifibatide selectively and reversibly binds to and blocks the platelet glycoprotein IIb/IIIa… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
BACKGROUND Glycoprotein IIb/IIIa inhibitors are indicated in patients with acute coronary syndromes who are undergoing an… (More)
  • figure 1
  • table 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND Pretreatment is not the most common strategy practiced for clopidogrel administration in elective coronary stenting… (More)
  • table 1
  • table 2
  • figure 1
  • figure 4
  • figure 2
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Highly Cited
2003
CONTEXT The direct thrombin inhibitor bivalirudin has been associated with better efficacy and less bleeding than heparin during… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Acute thrombocytopenia is a recognized complication of treatment with GPIIb/IIIa inhibitors whose cause is not yet known. We… (More)
  • table 1
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
Highly Cited
2000
Highly Cited
2000
BACKGROUND The platelet glycoprotein IIb/IIIa inhibitors, although effective in reducing ischaemic complications of percutaneous… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2000
Highly Cited
2000
BACKGROUND Appropriate treatment policies should include an accurate estimate of a patient's baseline risk. Risk modeling to date… (More)
  • table 1
  • table 2
  • table 2
  • figure 1
  • figure 2
Is this relevant?
Review
1999
Review
1999
BACKGROUND The primary cause of acute coronary syndromes is the development of a thrombus, a pathologic manifestation of platelet… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
  • The New England journal of medicine
  • 1998
BACKGROUND Aggregation of platelets is the pathophysiologic basis of the acute coronary syndromes. Eptifibatide, a synthetic… (More)
Is this relevant?
Review
1997
Review
1997
Activation of receptor function of platelet membrane glycoprotein (GP) IIb-IIIa leads to the binding of fibrinogen and is the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?